US-based skincare company La Lumiere received $20m in series B funding on Tuesday from Johnson & Johnsoon Development Corporation, the corporate venturing unit of healthcare company Johnson & Johnson, and venture capital firm Swan & Legend Venture Partners.
La Lumiere develops light-based phototherapy devices. The company’s debut product is the IlluMask, which offers treatments to the home market previously only available in dermatology offices.
The funding will support the commercialisation of IlluMask across the US, as well as the research and development of upcoming products. La Lumiere previously raised $4.1m in September 2013, according to an SEC filing.
Jay Tapper, founder and chief executive of La Lumiere, said: “This funding will help our technologies to reach exponentially more people, we’re confident in the market potential, La Lumiere’s intellectual property and our numerous competitive advantages.”